Eli Lilly’s Drug Cuts COVID-19 Recovery Time In Remdesivir-Combo Study-Reuters

Eli Lilly and Co said on Monday its rheumatoid arthritis drug shortened the time to recovery in hospitalized COVID-19 patients when used along with Gilead Sciences Inc’s remdesivir. The drug baricitinib, branded as Olumiant, cut the median recovery time by about a day when added to remdesivir, compared to patients treated with the antiviral alone, Lilly said. Reuters, 09/14/2020

•   Print
•   Email
•   Share
•   Tweet